文献速递慢阻肺

慢阻肺的当代视角:患者负担、性别作用与多病共存轨迹

Contemporary perspectives in COPD: Patient burden, the role of gender and trajectories of multimorbidity.
PubMed 文献 · Respirology · 2021-03-09

本文综述慢阻肺患者负担、女性疾病负担被低估及多病共存轨迹三个主题。慢阻肺常合并多种疾病,女性患病率自2008年在许多高收入国家已与男性持平,且女性对吸烟和污染物易感性更高、生活质量受损更重。治疗药物在男女中趋势相似但研究不足,临床试验男性居多,需加强性别特异性疗效预测研究。

要点

  • 慢阻肺常合并多种疾病,多病共存是常态而非例外。
  • 许多高收入国家女性慢阻肺患病率自2008年已与男性持平。
  • 女性对吸烟和污染物易感性更高,生活质量受损更重。

核心结论

  • 慢阻肺负担需关注女性人群和多病共存轨迹,预防和可干预因素至关重要。

研究设计与样本

  • 综述,整合三个主题:慢阻肺总体疾病负担、女性被低估的高负担、慢阻肺轨迹与其他非传染性疾病及多病模式的对比。

主要发现

  • 多病共存是慢阻肺的常态而非例外,多数患者合并其他医学问题,可降低整体生活质量。
  • 许多高收入国家女性慢阻肺患病率自2008年已与男性持平,低收入的生物质燃料暴露也是原因之一。
  • 美国女性主要死因中慢阻肺居前列,部分国家女性归因于慢阻肺的死亡率预测将在未来十年超过男性。
  • 女性对吸烟和污染物的易感性证据增加,且生活质量受损更显著。
  • 支气管舒张剂和吸入糖皮质激素在男女中预防急性加重和改善肺功能的趋势相似,但该领域研究不足,临床试验常以男性为主。

临床怎么用

  • 临床应认识女性慢阻肺负担增加,关注女性患者的生活质量损害和易感性。
  • 治疗决策需考虑性别对疗效预测的影响,但现有证据有限,需更多研究。
  • 对慢阻肺患者应评估多病共存,关注肺功能轨迹与后续慢性病的时序关联。
  • 卫生和社会照护系统需确保所有慢阻肺患者可及有效治疗,并实施预防策略。

局限性

  • 治疗药物性别差异的领域研究不足,临床试验常以男性为主。
  • 需进一步研究早期生活危险因素如何影响慢阻肺和其他疾病的轨迹及多病模式。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

An individual's experience of COPD is determined by many factors in addition to the pathological features of chronic bronchitis and emphysema and the symptoms that derive directly from them. Multimorbidity is the norm rather than the exception, so most people with COPD are living with a range of other medical problems which can decrease overall quality of life. COPD is caused by the inhalation of noxious particles or gases, in particular tobacco smoke, but also by early life disadvantage impairing lung development and by occupations where inhaled exposures are common (e.g. industrial, farming and cleaning work). Wealthy people are therefore relatively protected from developing COPD and people who do develop the condition may have reduced resources to cope. COPD is also no longer a condition that predominantly affects men. The prevalence of COPD among women has equalled that of men since 2008 in many high-income countries, due to increased exposure to tobacco, and in low-income countries due to biomass fuels. COPD is one of the leading causes of death in women in the USA, and death rates attributed to COPD in women in some countries are predicted to overtake those of men in the next decade. Many factors contribute to this phenomenon, but in addition to socioeconomic and occupational factors, there is increasing evidence of a higher susceptibility of females to smoking and pollutants. Quality of life is also more significantly impaired in women. Although most medications (bronchodilators and inhaled corticosteroids) used to treat COPD demonstrate similar trends for exacerbation prevention and lung function improvement in men and women, this is an understudied area and clinical trials frequently have a preponderance of males. A better understanding of gender-based predictors of efficacy of all therapeutic interventions is crucial for comprehensive patient care. There is an urgent need to recognize the increasing burden of COPD in women and to facilitate global improvements in disease prevention and management in this specific population. Many individuals with COPD follow a trajectory of both lung function decline and also multimorbidity. Unfavourable lung function trajectories throughout life have implications for later development of other chronic diseases. An enhanced understanding of the temporal associations underlying the development of coexisting diseases is a crucial first step in unravelling potential common disease pathways. Lessons can be learned from exploring disease trajectories of other NCD as well as multimorbidity development. Further research will be essential to explain how early life risk factors commonly influence trajectories of COPD and other diseases, how different diseases develop in relation to each other in a temporal way and how this ultimately leads to different multimorbidity patterns in COPD. This review integrates new knowledge and ideas pertaining to three broad themes (i) the overall burden of disease in COPD, (ii) an unappreciated high burden in women and (iii) the contrast of COPD trajectories and different multimorbidity patterns with trajectories of other NCD. The underlying pathology of COPD is largely irreversible, but many factors noted in the review are potentially amenable to intervention. Health and social care systems need to ensure that effective treatment is accessible to all people with the condition. Preventive strategies and treatments that alter the course of disease are crucial, particularly for patients with COPD as one of many problems.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Buttery SC, Zysman M, Vikjord SAA, et al. Contemporary perspectives in COPD: Patient burden, the role of gender and trajectories of multimorbidity. Respirology. 2021. PMID: 33751727. doi:10.1111/resp.14032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。